Closeup of a hand holding a model brain

Chambers-Grundy Center for Transformative Neuroscience News

The Chambers-Grundy Center for Transformative Neuroscience provides an academic platform for research and learning opportunities regarding the study of drug development for Alzheimer's disease and other brain disorders. It includes a clinical trials observatory for tracking new treatments, trial designs, and biomarkers in clinical trials for neurodegenerative disorders.

Current Center for Transformative Neuroscience News

people doing research
Research | December 27, 2021

UNLV researchers made international headlines this year with their discoveries. Here's a roundup of some of our top stories of 2021.

Portrait of Jefferson W. Kinney, Ph.D. Professor and Reg Grundy and Joy Chambers-Grundy Chair for Brain Health
People | July 26, 2021

The longtime UNLV researcher on youthful curiosity, the brain, and sports.

artist rendering of brain
Campus News | June 15, 2020

The Chambers-Grundy Center for Transformative Neuroscience will advance research and the science of treatment for Alzheimer’s and other neurological disorders.

A portrait of Jefferson Kinney in front of a brain scan.
Research | December 4, 2019

UNLV’s new Department of Brain Health leads interdisciplinary effort to answer tough questions about traumatic brain injury.

A man in a labcoat is reflected in nearby glass.
Campus News | September 26, 2019

Lou Ruvo Center for Brain Health neurologist Dr. Jeffrey Cummings joins UNLV to help launch new program that will be crucial for an aging state population.

Center for Transformative Neuroscience In The News

January 14, 2022

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

January 5, 2022

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

Las Vegas Review Journal
December 10, 2021

It’s called the Chambers-Grundy Center for Transformative Neuroscience at UNLV, and the adjective in the name says it all.

Neurology Live
October 22, 2021

Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.

October 21, 2021

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

October 13, 2021

NSUmethanide, an already approved drug for the treatment of swelling associated with conditions such as heart failure, improved cognitive test performance and reduced the accumulation of amyloid plaques in mice with conditions like Alzheimer’s disease.

Center for Transformative Neuroscience Experts

An expert in behavioral neuroscience with concentrations in Alzheimer's disease and schizophrenia.
A renowned expert on Alzheimer's Disease and other neurodegenerative disorders. 

Recent Center for Transformative Neuroscience Accomplishments

July 29, 2021
Dr. Jeff Cummings (Brain Health) published "Trial of Pimavanserin in Dementia-Related Psychosis" in the New England Journal of Medicine.       
July 19, 2021
Jeffrey Cummings (Brain Health) co-authored a paper published in Nature on developing the ATX(N) classification, a system for recognizing biomarkers in blood that indicate the presence in the brain of plaques and tangles characteristic of Alzheimer’s disease.  ATX(N) advances allow researchers to diagnose Alzheimer’s disease without…
June 19, 2020
Dr. Jeffrey Cummings (Brain Health) recently published an article outlining a novel method for determining whether Alzheimer’s drug treatments in clinical trials are ready to move on to the next phase. The paper, “Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach,” was published in The Journal of Dementia…
May 11, 2020
Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials in…
April 29, 2020
Dr. Jeffery Cummings (Brain Health) and other members of a joint European Union/United States Task Force recently published, “Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease” in the Journal of Prevention of Alzheimer’s Disease. In recognition of the complexity of the disease, the task force acknowledges it may require…
April 10, 2020
Dr. Jeffrey Cummings (Brain Health), recently published an article, “An Actigraphy-Based Validation Study of the Sleep Disorder Inventory (SDI) in the Nursing Home" in Frontiers in Psychiatry. It studied the use of the SDI to identify disrupted sleep in dementia patients in nursing homes, which was proven to be useful when done properly…